Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary.

Publication Year: 2024

DOI:
10.1002/cam4.6988

PMCID:
PMC10895198

PMID:
38404120

Journal Information

Full Title: Cancer Med

Abbreviation: Cancer Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"data s1."

Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT NC—outside the scope of the work presented, research funding/educational research grants have been received by the Experimental Cancer Medicine Team (PI: Cook) from AstraZeneca, Bayer, Pfizer, Orion, Taiho Oncology, Roche, Starpharma, Eisai, RedX, UCB, Boeringher, Merck, Stemline Tarveda and Avacta. The remaining authors have no conflicts to declare."

Evidence found in paper:

"FUNDING INFORMATION This work was supported by the University of Edinburgh, Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, Edinburgh, UK."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025